For help on how to get the results you want, see our search tips.
1739 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Shortages Remove Shortages filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Rybrevant (updated)
amivantamab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 09/12/2021,
, 
, Revision: 2, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna) (updated)
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021,
, , Revision: 35, Authorised, Last updated: 03/02/2023
-
List item
Human medicine European public assessment report (EPAR): Comirnaty (updated)
Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020,, , Revision: 38, Authorised, Last updated: 03/02/2023
-
List item
Human medicine European public assessment report (EPAR): Darunavir Krka d.d. (updated)
darunavir, HIV Infections
Date of authorisation: 18/01/2018,
, Revision: 8, Withdrawn, Last updated: 03/02/2023
-
List item
Human medicine European public assessment report (EPAR): Truvada (updated)
emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 20/02/2005, Revision: 46, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Stribild (updated)
elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate, HIV Infections
Date of authorisation: 24/05/2013, Revision: 25, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Bemrist Breezhaler (updated)
indacaterol, Mometasone furoate, Asthma
Date of authorisation: 30/05/2020, Revision: 5, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Atectura Breezhaler (updated)
indacaterol acetate, Mometasone furoate, Asthma
Date of authorisation: 30/05/2020, Revision: 7, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Lynparza (updated)
Olaparib, Ovarian Neoplasms
Date of authorisation: 16/12/2014, Revision: 19, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): DuoPlavin (updated)
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 14/03/2010, Revision: 27, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Karvezide (updated)
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 16/10/1998, Revision: 44, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Segluromet (updated)
ertugliflozin l-pyroglutamic acid, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 23/03/2018, Revision: 6, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Lyxumia (updated)
lixisenatide, Diabetes Mellitus, Type 2
Date of authorisation: 31/01/2013, Revision: 17, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Veklury (updated)
remdesivir, Coronavirus Infections
Date of authorisation: 03/07/2020,, Revision: 17, Authorised, Last updated: 02/02/2023
-
List item
Human medicine European public assessment report (EPAR): Praluent (updated)
Alirocumab, Dyslipidemias
Date of authorisation: 23/09/2015, Revision: 19, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Ceprotin (updated)
human protein C, Purpura Fulminans; Protein C Deficiency
Date of authorisation: 16/07/2001, Revision: 18, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Revinty Ellipta (updated)
fluticasone furoate, vilanterol trifenatate, Asthma
Date of authorisation: 02/05/2014, Revision: 21, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Karvea (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 45, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Relvar Ellipta (updated)
fluticasone furoate, vilanterol, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 13/11/2013, Revision: 24, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Blitzima (updated)
rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017,
, Revision: 18, Authorised, Last updated: 02/02/2023
-
List item
Human medicine European public assessment report (EPAR): Locametz (updated)
gozetotide, Radionuclide Imaging
Date of authorisation: 09/12/2022, Revision: 1, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Juluca (updated)
dolutegravir sodium, rilpivirine hydrochloride, HIV Infections
Date of authorisation: 16/05/2018, Revision: 14, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Cosentyx (updated)
Secukinumab, Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing
Date of authorisation: 14/01/2015, Revision: 28, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Tesavel (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 10/01/2008, Revision: 27, Authorised, Last updated: 02/02/2023 -
List item
Human medicine European public assessment report (EPAR): Pluvicto (updated)
lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 09/12/2022,, Revision: 1, Authorised, Last updated: 02/02/2023